To test the safety switch in vitro, we transduced CT2A, an immune-suppressive syngeneic GBM cell line (21), with the RIPK3 lentiviral construct, resulting in the engineered CT2A cell line (hereafter referred to as CT2A-RIPK3). The gene discussed is RIPK3; the disease is glioblastoma.